HeartCare-B Surges Over 15.7% to Near Two-Year High as Three Innovative Neurointerventional Products Debut

Gelonghui June 16 | HeartCare-B (6609.HK) surged over 15.7%, reaching a high of HK$39.4, hitting a nearly two-year high.

In terms of news, recently, the Oriental Conference on Cerebrovascular Diseases (OCIN 2025) and the World Live Neurovascular Conference (WLNC) were held jointly for the first time. HeartCare made a significant appearance with China's first domestically produced auxiliary stent for intracranial aneurysm embolization "Great Wall," the first coated flow diverter "Ruyi," and the revolutionary thrombectomy technology "CATCH Cascade." These three innovations not only fill the gap in China's high-end medical device sector but also enter the global technological competition with differentiated innovation.

In addition, the "Measures to Optimize Lifecycle Regulation and Support Innovation in High-End Medical Devices (Draft for Public Comment)" released earlier this year explicitly proposes promoting alignment with international standards, establishing a "Special Review for Innovation" fast track, and fully supporting major innovations in high-end medical devices. HeartCare, a company engaged in the research and development of innovative neurointerventional medical devices, is expected to benefit from this policy support. (Gelonghui)